Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation is a paper indexed in PICO Portal from OpenAlex.
How many citations does Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation have?
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation has 161 citations in the OpenAlex counts PICO Portal stores.
When was Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation published?
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation has 2021 year in the PICO Portal index.
What is the open-access status of Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation?
Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation has bronze oa status in the PICO Portal index.
What is the DOI of Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation?
The DOI for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation is on the source record.
What is the PMID of Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation?
The PMID for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation is on the source record.
What is the OpenAlex record for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation?
The OpenAlex for Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation is on the source record.